M.Sc. (Pharm.)
PREP in Neurodegenerative Disorders Group Researcher
PhD student

PhD student Mirva Hannula is working with the toxin models of α-synuclein. Her project consists of the development of the rotenone model for cells and in vivo, and the use of overexpressing cells with oxidative stress.

Education

M.Sc. (Pharm.),  University of Helsinki, 2012

• Main subject pharmacology

Publications

Hannula MJ, Männistö PT, Myöhänen TT: Sequential expression, activity and nuclear localization of prolyl oligopeptidase in the developing rat brain. Developmental Neuroscience 33: 38-47, 2011

Myöhänen TT, Hannula MJ, Van Elzen R, Gerard M, Van Der Veken P, Baekelandt V, Männistö PT, Lambeir AM: The prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson’s disease. British Journal of Pharmacology, 166:1097-1113, 2012

Hannula MJ, Myöhänen TT, Tenorio-Laranga J, Männistö PT, Garcia-Horsman JA: Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases. Neuroscience 242:140-150, 2013

Dokleja L, Hannula MJ, Myöhänen TT: Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers. Neurosci Lett. 583C:37-42, 2014